Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: A series of 157 cases from the MESOPATH group

Journal of Thoracic Oncology

Volumn 7, Issue 3, 2012, Pages 599-606

  Levallet, Guénaëlle ^a,b   Vaisse Lesteven, Mélissa ^b   Le Stang, Nolwenn ^b   Ilg, Anabelle Gilg Soit ^c   Brochard, Patrick ^c   Astoul, Philippe ^c   Pairon, Jean Claude ^c   Bergot, Emmanuel ^b   Zalcman, Gérard ^b   Galateau Sallé, Francoise ^a,b  

^a MESOPATH Center   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c PNSM INVs DST   (France)

Author keywords

C MET; HGF; Malignant pleural mesothelioma; Phospho c MET

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL MEMBRANE; CELLULAR DISTRIBUTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MESENCHYME CELL; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL;

EID: 84857921148     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182417da5     Document Type: Article

References (24)

1. Harvey P, Clark IM, Jaurand MC, et al. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 2000;83:1147-1153.
2. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006;66:352-361. (Pubitemid 43166042)
3. Kawaguchi K, Murakami H, Taniguchi T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009;30:1097-1105.
4. Klominek J, Baskin B, Liu Z, et al. Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 1998;76:240-249. (Pubitemid 28180379)
5. Tolnay E, Kuhnen C, Wiethege T, et al. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 1998;124:291-296. (Pubitemid 28332909)
6. Suzuki Y, Sakai K, Ueki J, et al. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 2010;127:1948-1957.
7. Ramos-Nino ME, Scapoli L, Martinelli M, et al. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 2003;63:3539-3545. (Pubitemid 36793033)
8. Gomes DA, Rodrigues MA, Leite MF, et al. c-Met must translocate to the nucleus to initiate calcium signals. J Biol Chem 2008;283:4344-4351.
9. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)
10. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000;19:5582-5589.
11. Hammond DE, Carter S, Clague MJ. Met receptor dynamics and signalling. Curr Top Microbiol Immunol 2004;286:21-44. (Pubitemid 38955146)
12. Harvey P, Warn A, Newman P, et al. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 1996;180:389-394. (Pubitemid 27014076)
13. Iwatsubo Y, Matrat M, Michel E, et al. Estimation of the incidence of pleural mesothelioma according to death certificates in France. Am J Ind Med 2002;42:188-199.
14. Le Stang N, Belot A, Gilg Soit Ilg A, et al. Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005. Int J Cancer 2010;126:232-238.
15. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133:1317-1331.
16. Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004;64:9027-9034. (Pubitemid 39665513)
17. Hurst HC, Masson N, Jones NC, et al. The cellular transcription factor CREB corresponds to activating transcription factor 47 (ATF-47) and forms complexes with a group of polypeptides related to ATF-43. Mol Cell Biol 1990;10:6192-6203. (Pubitemid 120004561)
18. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-1489.
19. Ebert M, Yokoyama M, Friess H, et al. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994;54:5775-5778. (Pubitemid 24375202)
20. Tsarfaty I, Resau JH, Rulong S, et al. The met proto-oncogene receptor and lumen formation. Science 1992;257:1258-1261.
21. Orian-Rousseau V, Chen L, Sleeman JP, et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074-3086. (Pubitemid 35424194)
22. Orian-Rousseau V, Morrison H, Matzke A, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 2007;18:76-83. (Pubitemid 46066712)
23. Kanteti R, Nallasura V, Loganathan S, et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009;89:301-314.
24. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46:1271-1277.